Plasma neuropeptide Y levels and adverse clinical outcomes after acute ischaemic stroke

What Was Tested

This randomized controlled trial paper looks at Neuropeptide Y.

Neuropeptide Y (NPY) has been reported to be involved in the pathophysiology of several cardiovascular disease processes and might contribute to the incidence of stroke, but the prognostic utility of circulating NPY after acute ischaemic stroke is unclear.

This study aimed to prospectively examine the association between plasma NPY levels and adverse clinical outcomes after acute ischaemic stroke.

Who Took Part

The abstract describes 3250 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Plasma NPY levels were measured in 3250 patients (2066 men and 1184 women) from the China Antihypertensive Trial in Acute Ischaemic Stroke.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Neuropeptide Y study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

The subject headings attached to it are Neuropeptide Y, Ischemic Stroke, Biomarkers, Prognosis, China and Brain Ischemia.

The authors tagged it with the keywords ischaemic stroke and risk prediction.

What This Means in Plain Language

The paper is a randomized study of Neuropeptide Y in 3250 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (European journal of neurology), a journal based in England.

More context: the Neuropeptide Y compound page, all human trials.